Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 10, 2026Leukemia & lymphoma/Leukemia and lymphoma

Improved overall survival in acute myeloid leukemia over the last 15 years

View Full Paper
Ask AI
Bookmark
Share

Authors

SSShailesh SimkhadaLALuna AcharyaBLBradley T. Loeffler

Discussion

Loading...

Member takes

Overview

Analysis shows improved survival rates in acute myeloid leukemia, indicating progress in treatment approaches.

Key Points

  • This research aims to evaluate overall survival changes in acute myeloid leukemia (AML) patients over a 15-year period.
  • Analyzed data from the National Cancer Database.
  • Included 67,895 AML patients aged 18 and older.
  • Divided patients into three diagnosis eras: 2004-2010, 2011-2016, and 2017-2019.
  • Median overall survival increased: 7.6 months (2004-2010), 8.6 months (2011-2016), 10.4 months (2017-2019).
  • Stronger positive associations with chemotherapy and hematopoietic cell transplantation were noted after 2017.
  • Survival disparities persisted based on sex, race, age, insurance status, and income.

Cite This Study

Simkhada et al. (2026) studied this question.

synapsesocial.com/papers/69af95de70916d39fea4ddebhttps://doi.org/10.1080/10428194.2026.2635662
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML2022 · 36 citations
  2. 2Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML2018 · 1,470 citations
  3. 3Disparities in speed to BMT consult and allograft in 279 adults with AML.2022 · 1 citations
  4. 4CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia2018 · 1,017 citations
  5. 5FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia2018 · 335 citations